

Protalix BioTherapeutics, Inc.  
Form 8-K  
November 16, 2015

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 16, 2015**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

**Florida  
(State or other jurisdiction  
of incorporation)**

**001-33357**

**(Commission File Number)**

**65-0643773  
(IRS Employer**

**Identification No.)**



**Item 8.01. Other Events**

On November 16, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that it recently held an End-of-Phase II meeting with the U.S. Food and Drug Administration to discuss the Company’s proposed Biologics License Application (BLA) plan for PRX-102 for the treatment of Fabry disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated November 16, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: November 16, 2015 By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Vice President and Chief Financial Officer